The current standard of care for identifying targetable mutations in cancer treatment is to conduct molecular profiles on tumor tissue samples, but a study published Monday in JAMA Network Open authored by Wade Iams, MD, and colleagues indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.
https://news.vumc.org/2024/01/22/molecular-profiles-of-tissue-plus-circulating-tumor-dna-can-better-guide-cancer-care/
Kelley Robbins
Locked